Pharma Stocks
-
Healthcare Value Stocks Regain Attention As Market Leadership Shifts
Disclaimer The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos,…
Read More » -
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Strong Longer Term Returns
Tarsus Pharmaceuticals (TARS) has been drawing attention after recent trading swings, with the stock closing at US$59.64 while showing mixed…
Read More » -
Insider Buyers At aTyr Pharma Likely Disappointed With 19% Slide
The recent 19% drop in aTyr Pharma, Inc.’s (NASDAQ:ATYR) stock could come as a blow to insiders who purchased US$911.8k…
Read More » -
Why Eli Lilly Stock Climbed to a New All-Time High Today
Shares of Eli Lilly (LLY +1.56%) rose to a record high on Monday after the medicine maker announced positive clinical…
Read More » -
A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Recent Share Price Cooling
Event context and recent stock move Indivior Pharmaceuticals (INDV) has been attracting attention after a mixed stretch in its share…
Read More » -
Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Recent Share Price Weakness
Recent share performance and business snapshot Ascendis Pharma (NasdaqGS:ASND) stock has been under pressure recently, with the share price down…
Read More » -
Is First-in-Class FDA Approval For XOCOVA PEP Altering The Investment Case For Shionogi (TSE:4507)?
Shionogi announced that the U.S. FDA has approved XOCOVA (ensitrelvir) as the first oral antiviral for post-exposure prophylaxis of COVID-19…
Read More » -
Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
© ipopba / iStock via Getty Images After years of lagging the market, healthcare may be taking on a new…
Read More » -
Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
Quick Read Merck’s Keytruda posted $8 billion in Q1 sales, while Summit’s ivonescimab faces binary risk ahead of its November…
Read More » -
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million
Andrew Reardon, CLO & Secretary at Ligand (LGND +0.46%), reported the sale of 5,000 shares of Common Stock for approximately…
Read More »